Low rate of macrolide resistance in Mycoplasma pneumoniae strains in Germany between 2009 and 2012.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The role of the PM2.5-associated metals in pathogenesis of child Mycoplasma Pneumoniae infections: a systematic review.Environmental science and pollution research international · 2016
   Pooled it
2. [Macrolide-resistant Mycoplasma pneumoniae: Do we know the situation in Europe?]Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023
   Review
3. Update on the Epidemiology of Macrolide-ResistantInfectious disease reports · 2021
   Review
4. Point-of-care molecular diagnosis of Mycoplasma pneumoniae including macrolide sensitivity using quenching probe polymerase chain reaction.PloS one · 2021
   Article
5. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020
   Article
6. Long-Term Low Rate of Macrolide-ResistantAntimicrobial agents and chemotherapy · 2019
   Article
7. Mycoplasma pneumoniae from the Respiratory Tract and Beyond.Clinical microbiology reviews · 2017
   Review
8. In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.Antimicrobial agents and chemotherapy · 2017
   Article
9. Mycoplasma pneumoniae: Current Knowledge on Macrolide Resistance and Treatment.Frontiers in microbiology · 2016
   Review
10. No detection of macrolide-resistant Mycoplasma pneumoniae from Swedish patients, 1996-2013.Infection ecology & epidemiology · 2016
    Article
11. Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China.Antimicrobial agents and chemotherapy · 2015
    Article
12. Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications.Frontiers in microbiology · 2014
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as